The role of radiotherapy for the immunotherapy of esophageal squamous cell carcinoma: translational approach and future pathways—a narrative review
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background and Objective: The prognosis of esophageal cancer remains poor, prompting the development of various multimodal treatment strategies. The CROSS trial highlighted the efficacy of neoadjuvant chemoradiotherapy (CRT), establishing it as a standard approach in resectable locally advanced esophageal cancer. However, results from subsequent trials such as NEO-AEGIS and ESOPEC demonstrated the superiority of perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) in adenocarcinoma, leading recent CRT-based developments to focus primarily on esophageal squamous cell carcinoma (ESCC). The synergistic effects of radiotherapy (RT) and immune checkpoint inhibitors (ICIs) have been demonstrated across multiple malignancies. The phase III CheckMate 577 trial further showed a clear benefit of sequential nivolumab after neoadjuvant CRT in patients with resected esophageal cancer. Consequently, the integration of RT and ICI is now being actively explored, mainly in ESCC. This narrative review aims to summarize the current clinical evidence and ongoing trials of immunoradiotherapy in ESCC, and to highlight key translational research that requires further validation. Methods: This narrative review includes studies identified through PubMed and ClinicalTrials.gov search conducted up to October 31, 2025. Only publications written in English were considered. Key Content and Findings: Although long-term outcomes remain limited, the combination of RT and ICI has demonstrated significant benefits in pathological or clinical complete response rates. The eagerly anticipated SKYSCRAPER-07 trial—the first phase III study of RT and ICI in unresectable locally advanced ESCC—unfortunately failed to show a benefit for dual TIGIT and PD-L1 blockade after definitive CRT, whereas sequential ICI monotherapy showed numerically favorable outcomes. Several phase III trials investigating concurrent RT and ICI are ongoing, and their outcomes are awaited. Conclusions: Immunoradiotherapy represents a promising strategy for ESCC, but its survival benefit, optimal sequencing, and appropriate patient selection remain uncertain. Ongoing randomized trials and biomarker-driven translational research will be essential to establish clinically meaningful endpoints and define the future role of RT–ICI combinations in ESCC management.
Fields of Study & Subjects
Esophageal Cancer Research and Treatment
Cancer Immunotherapy and Biomarkers
Head and Neck Cancer Studies
Publication details
- Journal / source
- Annals of Esophagus
- Volume
- 9
- Pages
- 4–4
- Publication date
- 1 March 2026
- Language
- EN